Find Nina Patrick here: https://qrco.de/bgXpKn

----------

Sponsor: GlycanAge

Inflammaging drives CVD, metabolic disorders, and accelerated aging, but clinicians still lack reliable tools to measure, intervene, and track it in practice. GlycanAge brings together leading experts to close that gap with practical frameworks for assessing immune aging in real-world clinical settings.

Register via the link below and join the one-day event to learn how to measure immune aging and apply it to preventive and longevity care.

Date: June 20 2026 | Location: Hotel Dubrovnik Palace, Croatia

Link: https://glycanage.com/inflammaging-in-clinical-practice

----------

Guests: Nikolina Lauc

CEO & Co-Founder of GlycanAge

LinkedIn: https://www.linkedin.com/in/nikolinalauc/

Website: https://glycanage.com/

----------

What if glycans—the neglected sugars on immune proteins—reveal inflammation and biological age more accurately than DNA methylation or CRP?

Phil Newman and Dr. Nina Patrick sit down with Nikolina Lauc, CEO and co-founder of GlycanAge, to explore how these biomarkers integrate genetics, epigenetics, and environment for superior aging insights.

Together they explain glycan shifts predicting cardiovascular events better than standard markers, with 300,000+ samples showing changes up to 10 years before diabetes. From perimenopause accelerating biological age by nine years (or decades in months for some) to moderate exercise yielding 10 years younger profiles versus pros matching sedentary inflammation, these reveal immune-driven aging realities. Contrasting epigenetic clocks' 10% variability (five-year swings same-day), glycans stay stable within one year.

They also discuss hormone replacement reversing effects, fasting dropping profiles in days despite 21-day half-life, overtraining myths, and psychology like PTSD adding 15 years immune age—pushing immune resilience scores over raw age.

In this episode, you’ll learn:

• Glycans predict CV risk/mortality across 350+ papers, outperforming CRP
• Perimenopause doubles aging rate; estrogen reverses 9-year spike
• Over-exercisers match sedentary inflammation; moderates gain 10 years
• Fasting alters glycans in days vs 21-day half-life
• Stress/divorce adds decades; PTSD shortens expectancy 15-20 years
• Glycans enable modifiable risk scores for hospitals like Northwestern

If you want to understand why inflammation may be the true driver of aging, this episode connects large-scale glycan data with real-world clinical implications for prevention and longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

Find Nina Patrick here: https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine epigenetic consolidation, SuperAge Games, Endless funding, Genflow gene therapy partnership, knee implants, and longevity business models.

• Infinite Epigenetics acquired Tally Health, gaining its cheek swab biological age test and supplement recommendations. Largest epigenetic datasets could edge personalized medicine.
• SuperAge announced the SuperAge Games in New York this November, a healthspan-focused competition like CrossFit testing endurance, strength, balance, cognition, and social capacity via biomarkers. It reframes athleticism for durability over intensity, celebrating competitors at 50-70. Contrasts enhanced games by prioritizing sustained resilience.
• Endlyz closed Seed 2 funding for root-cause neurodegeneration targeting beyond plaques or inflammation. Aims for early causal interventions differing from symptom treatments. Needs specific mechanisms and biomarkers for credibility amid neuro translation challenges.
• Genflow Biosciences partnered with Acuitas Therapeutics on SIRT6 mRNA from centenarians for DNA repair, using proven lipid nanoparticles fully funded by Acuitas. De-risks delivery for preclinical tests in dogs and beyond and signals promise in aging gene therapy.
• Smith+Nephew's FDA-approved AGILI-C knee implant showed superior 5-year pain reduction and mobility in mild-moderate osteoarthritis. Targets treatment gap patients, with CPT reimbursement in 2027.
• Companies race longevity-ready models profiting from healthspan in healthcare to workplaces via screenings and benefits. Hard metrics on absenteeism excite employers at Longevity Show, and flips sickcare threats to assets.

----------

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

News & References:

• Infinite Epigenetics acquires Tally Health → https://longevity.technology/news/infinite-epigenetics-acquires-tally-health/
• Super Age debuts world’s first longevity fitness games → https://longevity.technology/news/super-age-debuts-worlds-first-longevity-fitness-games/
• Endlyz raises Seed 2 financing, leans into root-cause neuroscience → https://longevity.technology/news/endlyz-raises-seed-2-financing-leans-into-root-cause-neuroscience/
• Genflow teams with Acuitas on gene delivery in fully-funded deal → https://longevity.technology/news/genflow-teams-with-acuitas-on-gene-delivery-in-fully-funded-deal/
• Knee implant outperforms standard care at 5 years → https://longevity.technology/news/knee-implant-outperforms-standard-care-at-5-years/
• Inside the race to build longevity-ready business models → https://longevity.technology/news/inside-the-race-to-build-longevity-ready-business-models/

Find Nina Patrick here: https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

Guests:JJ Virgin

Founder of Health Business Growth Collective and Well Beyond 40

Instagram: https://www.instagram.com/jj.virgin/

Website: https://jjvirgin.com/

----------

What if the key to living longer wasn’t a pill, but making your body stronger?

Phil Newman and Dr. Nina Patrick sit down with JJ Virgin, triple board-certified nutrition expert, fitness hall of famer, and founder of the Health Business Growth Collective, to explore how muscle drives strength, resilience, and decades of high performance.

According to JJ, muscle quietly slips away after 30. Protein synthesis drops 30% per decade, hitting women earliest and hardest as perimenopause estrogen fades against their lower starting mass. Grip strength reveals the truth first, signaling all-cause mortality risk—the weakest quartile faces the steepest odds—even as 50% of normal-weight adults harbor sarcopenic obesity, blending frailty with hidden fat that rushes aging.

JJ cuts through the noise. Grip dynamometer tests deliver the simplest proxy: squeeze for "great" versus your age group, with under 10% hand asymmetry. She flips GLP-1s on their head—build muscle first with protein matched to ideal weight and fat-free mass tracking, then cut calories. Beginners start her 2x2x2: two days weekly, two moves per body part, two sets to near-failure. Neural gains arrive before the mirror notices.

In this episode, you’ll learn:

• Grip strength predicts mortality. Test 3x per side; track gains as neural adaptations lead hypertrophy by 6-8 weeks.
• Build muscle first. GLP-1s expose weak diets, risking 40% muscle loss on calorie cuts without resistance training.- Women lose fast-twitch fibers quickest. Challenge with 6-12 reps near failure to rebuild power.
• Resting metabolic rate climbs 7-10 calories per pound of muscle; protein-first meals spike thermic effect 25%.
• Start simple: pushups (wall to toes), squats to chair (30-sec power test), rows. Progress from bodyweight to loads.
• 40 years of clinical insights deliver actionable tests and programming against gravity's pull.

If you want to understand how muscle powers healthspan against gravity-fueled decline, this episode connects 40 years of clinical insights with actionable tests and programming for powerful aging.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

Find Nina Patrick here: https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine energy span as a fatigue biomarker, GSK's $950M 35 Pharma acquisition, January AI's Medicare app entry, OsteoBoost's $8M funding, Seragon's SRN-901 33% mouse lifespan boost, and skin longevity advances.

• Energy span proposes viewing fatigue as an early mitochondrial decline signal before chronic disease. Advances in wearable technology and continuous monitoring are making it possible to track proxies of energy regulation – heart rate variability as a marker of autonomic balance, glucose dynamics as a reflection of metabolic stability, sleep architecture as a proxy for recovery.
• GSK acquired 35Pharma for $950M, gaining a pulmonary hypertension candidate affecting lung arteries. Proof-of-concept trials are expected to begin soon in two forms of the disease: pulmonary arterial hypertension (PAH) and PH linked to heart failure with preserved ejection fraction (PH-HFpEF).
• January AI joined Medicare's app library for 69M users, using food photos and AI to predict glucose responses. It lowers barriers for metabolic coaching but needs integration and targeting for adoption.
• OsteoBoost raised $8M for a vibration wearable mimicking bone-loading to combat osteoporosis in 200M worldwide. It offers non-drug options amid bisphosphonate trade-offs, with mixed prior studies on dose.
• Seragon's oral SRN-901 extended late-life mouse lifespan 33%, cut frailty 70%, tumors 30% via mitophagy and NAD support, outperforming rapamycin.
• Epicutis' TCP serum improved skin appearance 77% in 8-week trial versus placebo, signaling cellular modulation in aesthetics.

----------

Hosts:Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

News & References:

• GSK acquires 35Pharma in $950m deal, advancing PH drug → https://longevity.technology/news/gsk-acquires-35pharma-in-950m-deal-advancing-ph-drug/
• Energy Span reframes fatigue as early warning → https://longevity.technology/news/energy-span-reframes-fatigue-as-early-warning/
• Osteoboost raises $8m to scale bone wearable → https://longevity.technology/news/osteoboost-raises-8m-to-scale-bone-wearable/
• January AI enters Medicare App Library, reaches 69m+ patients → https://longevity.technology/news/january-ai-enters-medicare-app-library-reaches-69m-patients/
• Seragon study shows SRN-901 extends median lifespan in mice → https://longevity.technology/news/seragon-study-shows-srn-901-extends-median-lifespan-in-mice/
• Epicutis clinical study shows 77% improvement in skin appearance → https://longevity.technology/news/epicutis-clinical-study-shows-77-improvement-in-skin-appearance/

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED

-----

Guest:

Tim GrayFounder, Health Optimization Summit

Website: https://healthoptimization.com/

Instagram: https://www.instagram.com/timbiohacker/

-----

What if biohacking is not about doing more, but about doing less, better?

Phil Newman and Dr. Nina Patrick sit down with Tim Gray, founder of the Health Optimization Summit and one of the most influential figures in the biohacking movement, to explore how the space has evolved from niche experimentation to mainstream health optimization. From supplements and wearables to nervous system regulation and community-driven health, Tim shares what actually moves the needle and what does not.

They discuss the shift from complex protocols to foundational health principles, why oversupplementation and excessive data can backfire, and how environment and lifestyle often outperform expensive technologies. The conversation also explores emerging trends including peptides, stem cells, microplastics, and the growing importance of nervous system regulation.

The episode examines how large-scale personal data is shaping health insights, the balance between personal experimentation and clinical evidence, and why loneliness may be one of the most overlooked risks to longevity.

In this episode, you will learn:

• How biohacking has evolved into health optimization
  Why simplifying your health routine often leads to better results
• The risks of oversupplementation and over-reliance on data
• How environment influences the need for health technologies
• The role of peptides and stem cells in the future of medicine
• Why nervous system regulation is becoming a central pillar of health
• The impact of community and relationships on longevity
• How to think about personalization versus foundational health principles

If you want to understand where the longevity and biohacking space is heading and how to focus on what actually works, this episode offers a grounded, experience-led perspective on optimizing health in a complex world.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.

-----

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore the $67B longevity market projection, Technogym’s Google partnership, Function Health’s acquisition, mitochondrial transplants, clinical education, and the rise of workforce healthspan.

A new report projects the longevity and healthy aging market will reach $67B by 2035, spanning therapeutics, diagnostics, supplements, and lifestyle interventions. Growth signals mainstream adoption, but raises concerns around “longevity washing” and the need for stronger scientific validation.

Technogym expands its partnership with Google Cloud to build AI-powered, personalized fitness and health coaching. Alongside moves from L’Oréal and wearables players, big tech and legacy brands are embedding longevity into everyday consumer platforms.

Function Health acquires GetLabs to enable at-home blood draws, removing friction in biomarker testing. The move strengthens longitudinal health tracking, though success depends on pairing access with meaningful clinical guidance.

Mitrix Bio reports early safety data on mitochondrial transplants, injecting lab-grown mitochondria to restore cellular energy. With only two participants and clinics already launching under “Right to Try,” the approach highlights tensions between innovation speed and clinical evidence.Longevity.Technology launches a clinical education marketplace, curating vetted training programs for clinicians, founders, and consumers. The platform aims to address fragmentation and raise standards across the rapidly evolving sector.

Employers are shifting toward healthspan-focused benefits, prioritizing diagnostics, mental health, and preventative care over traditional perks. Workforce longevity strategies are emerging as a key lever for productivity, retention, and cost control

.----------

Hosts:

Phil Newman: https://qrco.de/bgXpNYNina

Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

News & References:

Technogym & Google Cloud partnership → https://longevity.technology/news/technogym-and-google-cloud-expand-ai-fitness/

Function Health acquires GetLabs → https://longevity.technology/news/function-acquires-getlabs-to-scale-at-home-testing/

Mitrix Bio mitochondrial transplant trials → https://longevity.technology/news/mitrix-moves-mitochondria-into-the-clinic/

Longevity.Technology education marketplace launch → https://longevity.technology/news/education-platform-targets-longevity-knowledge-gap/

Workforce healthspan trends → https://longevity.technology/news/workers-rethink-benefits-healthspan-comes-first/

Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED______________________Guests:Dr Terry WahlsPhysician and Author of The Wahls ProtocolWebsite: https://terrywahls.com/______________________What if autoimmune disease isn’t irreversible, but a reflection of deeper dysfunction at the cellular level?Phil Newman and Dr. Nina Patrick sit down with Dr. Terry Wahls, clinician, researcher, and author of The Wahls Protocol, to explore how diet, lifestyle, and cellular health can reshape outcomes in chronic disease. Diagnosed with progressive multiple sclerosis and confined to a wheelchair, Dr. Wahls applied a science-led, systems-based approach to restore her function, challenging conventional assumptions about what is possible in autoimmune conditions.They explore how mitochondria, the microbiome, and immune function interact to drive disease, and how targeted interventions across nutrition, movement, and lifestyle can improve resilience, energy, and overall health.The conversation covers nutrient density, gut health, fasting, fats, and behavioural change, connecting clinical science with practical application. It also examines the resistance faced by non-traditional approaches in medicine, the difficulty of funding complex lifestyle research, and why personalised, systems-level thinking may shape the future of healthcare.In this episode, you will learn:

• How Dr. Wahls went from wheelchair-bound to walking and cycling again
• The role of mitochondria and cellular function in autoimmune disease
• How diet, gut health, and the microbiome influence immunity and brain health
• Why ultra-processed foods drive inflammation and chronic disease
• The importance of personalised nutrition and lifestyle interventions
• How to use “biosensors” to track what works for your body
• The limitations of current microbiome testing and one-size-fits-all diets

If you want to understand how science-backed lifestyle interventions can influence chronic disease, performance, and long-term health, this episode offers a clear and evidence-informed perspective on what is possible.Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

__________________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GeneRare funding, Noom's pharmacy buy, Anovis neuro combos, Life Biosciences reprogramming, wearable partnerships, and Peloton at Longevity Show.

• Generare raised $21.6M (€20M) Series A to scale microbial genome scanning for novel natural product molecules, identifying 200+ hits in 2025. Funds expand libraries from plants, fungi, marine sources and team to 50 for bioactive drug leads. AI optimizes hits despite supply/IP challenges, eyeing geroprotectors like rapamycin analogs.
• Noom acquired a 503A compounding pharmacy to dispense GLP-1s, peptides like sermorelin, NAD+ with behavioral coaching for healthy aging. Vertical integration pairs app data with pharma access to scale longevity interventions. Success needs strong clinical governance over revenue incentives.
• Annovis advances buntanetap, oral molecule from Calabar bean "execution poison," reducing amyloid beta, tau, alpha-synuclein translation in phase 3 Alzheimer's and Parkinson's trials. Combos with sildenafil boost cerebral blood flow, NO-cGMP as vascular support.
• Life Biosciences landed $80M Series D to push ER-100 partial epigenetic "cell reset" therapy into phase 1 for optic neuropathies like glaucoma. Targets retinal ganglion cell rejuvenation as beachhead for organ-specific proofs toward systemic aging reversal. Measurable vision outcomes validate reprogramming.
• Agentis partners Ultrahuman integrating CGM/HRV into Longevity Quotient platforms; Well Health ties AliveCor for AI-ECG AFib detection in Canada. Wearables enable dynamic monitoring beyond snapshots for arrhythmias, metabolic drift. Demand proven clinical outcomes over data noise.
• Peloton named official movement partner for Longevity Show 2026 (June 26-27, London) with rooftop workouts, 5K runs, rave featuring Leanne Hainesby. Anchors exercise as healthspan core alongside biomarkers, bridging fitness-longevity audiences. Preview April 19 Covent Garden.

______________________

News & References:

• Generare bags $21.6m for nature-derived drug leads → https://longevity.technology/news/generare-bags-21-6m-for-nature-derived-drug-leads/
• Noom buys pharmacy to push into healthy aging → https://longevity.technology/news/noom-buys-pharmacy-to-push-into-healthy-aging/
• Annovis traces buntanetap’s road to Alzheimer’s → https://longevity.technology/news/annovis-traces-buntanetaps-road-to-alzheimers/
• Life Biosciences lands $80m to push cell reset therapy → https://longevity.technology/news/life-biosciences-lands-80m-to-push-cell-reset-therapy/
• Agentis, Ultrahuman tie wearables to longevity care → https://longevity.technology/news/agentis-ultrahuman-tie-wearables-to-longevity-care/
• Peloton named Movement Partner for The Longevity Show 2026 → https://longevity.technology/news/peloton-named-movement-partner-for-the-longevity-show-2026/

______________________

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

______________________

Guests:

Ashley Zehnder

CEO, Fauna Bio

Linkedin: www.linkedin.com/in/ashley-zehnder-31950827/

Website: faunabio.com/

Daniel Oliver

Co-Founder & CEO, Rejuvenate Bio

Linkedin: www.linkedin.com/in/danielcoliver/

Website: rejuvenatebio.com/

______________________

What if the animal kingdom holds the key to improving human healthspan and performance?

Phil Newman and Dr. Nina Patrick sit down with Ashley Zehnder, CEO of Fauna Bio, and Daniel Oliver, CEO of Rejuvenate Bio, to explore how insights from hibernating animals, long-lived species, and regenerative models are shaping next-generation longevity therapies. From metabolic adaptations and ketone utilization to epigenetic reprogramming, they reveal how studying other species can guide interventions for human health, recovery, and overall wellness.

Together they explain how species that naturally resist disease, survive extreme conditions, or regenerate tissues provide a roadmap for interventions in humans. From hibernating mammals that switch to ketone-based metabolism to long-lived rodents showing epigenetic resilience, these insights are shaping therapies that target recovery, metabolism, and overall wellness.

They also discuss how these discoveries could inform practical strategies for human health, from personalized nutrition and exercise to novel drug targets that mimic nature’s resilience.

In this episode, you’ll learn:

• How gene therapies in animals improve endurance, recovery, frailty, and lifespan- What hibernating animals and high-performance species teach about metabolism and resilience
• How AI and comparative genomics accelerate drug discovery and improve translational success
• Common misconceptions about translating animal biology to human health
• Future priorities in longevity research, including regenerative biology and disease resistance

If you want to understand how comparative biology and cutting-edge therapies are unlocking new pathways to enhance human healthspan, this episode connects science from the animal kingdom with actionable insights for human longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

______________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine how early neurodegeneration screening, bioprinted tissues, senolytic therapies, pharma strategy shifts, and private clinic evolution are reshaping how longevity medicine is practiced and regulated.

• PREMAZ partnered with Health is One to expand access to early brain screening designed to detect neurodegenerative risk before symptoms appear. While full biomarker validation data has not yet been published, the initiative highlights the growing race to identify preclinical Alzheimer’s and dementia signals at a stage where lifestyle and therapeutic interventions may still alter trajectory.
• Eli Lilly continues assembling what increasingly resembles a longevity-aligned portfolio. Through AI drug discovery alliances, cardiometabolic dominance via GLP-1s, and deep investments across fibrosis, neurodegeneration, muscle, immune, and vascular aging, the company is building a multi-pathway prevention strategy even without using the term longevity publicly.
• Berlin-based startup Cellbricks secured €10 million to advance its vascularized 3D bioprinted tissue implants toward preclinical development. Solving the vascularization bottleneck in functional tissue printing could eventually transform how age-related organ failure is treated, reducing reliance on donor transplantation.
• Global advocacy efforts are intensifying to push regulators to classify aging itself as a modifiable condition rather than a background risk factor.
• Rubedo Life Sciences reported first human trial results for a topical senolytic therapy targeting senescent cells in patients with psoriasis and eczema. The treatment showed reduced senescent cell burden, lower inflammatory markers, and increased skin collagen thickness after four weeks, offering an early human proof of concept for targeted senotherapeutics.
• Private hospitals and premium clinics are increasingly repositioning themselves as longevity centers. With existing diagnostics, labs, imaging, and clinical teams, these facilities are well placed to transition from reactive sick care to proactive health span management. The challenge now is standardization, clinician training, shared biomarkers, and evidence-based protocols to prevent longevity medicine from becoming personality driven rather than data driven.

______________________

News & References:

• PREMAZ expands early brain screening through Health is One → https://longevity.technology/news/premaz-expands-early-brain-screening-through-health-is-one/
• Lilly races to become first longevity Big Pharma → https://longevity.technology/news/lilly-races-to-become-first-longevity-big-pharma/
• Cellbricks Therapeutics secures €10 million to advance tissue implants → https://longevity.technology/news/cellbricks-therapeutics-secures-e10-million-to-advance-tissue-implants/
• Global rallies call for aging to be treated → https://longevity.technology/news/global-rallies-call-for-aging-to-be-treated/
• Rubedo reports early clinical signal for senotherapeutic drug → https://longevity.technology/news/rubedo-reports-early-clinical-signal-for-senotherapeutic-drug/
• Private clinics face longevity learning curve → https://longevity.technology/news/private-clinics-face-longevity-learning-curve/

______________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠